How fast does glucagon work?

Injectable glucagon raises blood glucose within 10–15 minutes, with most patients regaining consciousness within 15–20 minutes. Nasal spray glucagon works similarly, typically within 12–15 minutes. This makes glucagon the fastest pharmacological treatment for severe hypoglycemia available.

Can I give glucagon to someone who is unconscious?

Yes—that's precisely when glucagon is most valuable. Unlike sugar or juice, glucagon doesn't require the person to be awake or able to swallow. It works via injection or nasal spray and will raise blood glucose even in unconscious patients, allowing them to regain consciousness within minutes.

Does glucagon have side effects?

Serious side effects are rare. Nausea and vomiting occur in fewer than 2% of cases. Mild hyperglycemia (high blood sugar) afterward is expected and normal. Allergic reactions are extremely uncommon. Glucagon has a well-documented excellent safety profile across over 1,000 clinical trials.

Who should carry glucagon?

Anyone taking insulin or diabetes medications that can cause low blood sugar should have glucagon available. Caregivers—family members, school staff, coworkers—should be trained to recognize severe hypoglycemia and administer glucagon. Both injectable and nasal formulations are recommended for maximum accessibility.

How is glucagon different from insulin?

Insulin lowers blood sugar; glucagon raises it. They work through opposite mechanisms: insulin promotes glucose uptake into cells, while glucagon triggers glucose release from liver and muscle stores. Together, they maintain blood glucose balance. Glucagon is the emergency treatment for insulin overdose or severe low blood sugar.

Glucagon: Mechanism, Clinical Uses & Regulatory Status

Glucagon is a 29-amino acid peptide hormone approved by the FDA, EMA, and Health Canada for treating severe hypoglycemia (dangerously low blood sugar). It works by triggering the liver and muscle to release stored glucose into the bloodstream, rapidly restoring blood sugar levels in emergency situations. Unlike insulin, which lowers blood sugar, glucagon acts as its physiological counterbalance—a critical safety net for people with diabetes who risk hypoglycemic episodes. With over 1,000 clinical trials documenting its efficacy and safety profile, glucagon remains one of the most well-studied peptide therapeutics in medical practice, available in multiple formulations from emergency injection kits to nasal sprays.

What Is Glucagon?

Glucagon is a peptide hormone produced naturally by alpha cells in the pancreas. It's a straightforward but powerful molecule: a chain of 29 amino acids that acts as insulin's functional opposite. When blood glucose drops too low—below 70 mg/dL is generally considered hypoglycemic—glucagon is released to trigger an emergency glucose release. As a therapeutic, glucagon has been synthesized and formulated into injectable and intranasal products that provide rapid glucose mobilization in minutes, making it a literal life-saving intervention for severe hypoglycemia.

How Glucagon Works: The Mechanism

Glucagon activates the glucagon receptor, a G-protein coupled receptor found predominantly on liver and muscle cells. When glucagon binds to this receptor, it triggers a cascade of intracellular signals that activate glycogenolysis (the breakdown of stored glycogen into glucose) and gluconeogenesis (the synthesis of new glucose from non-carbohydrate sources like amino acids and lactate).

The result is rapid: within 10–15 minutes of intramuscular or subcutaneous injection, blood glucose typically rises by 25–50 mg/dL. This makes glucagon the fastest-acting treatment for severe hypoglycemia, faster even than consuming sugar orally (which requires the person to be conscious and able to swallow). Research demonstrates that glucagon administration increases plasma glucose concentration within 5–10 minutes in hypoglycemic patients, and most patients regain consciousness and oral intake within 15–20 minutes.

Clinical Applications

Emergency Hypoglycemia Treatment

The primary indication for glucagon is acute severe hypoglycemia—blood glucose below 54 mg/dL with symptoms like loss of consciousness, seizures, or inability to self-treat. This is the most common life-threatening complication of insulin therapy in people with type 1 and type 2 diabetes. A landmark clinical trial involving over 1,800 hypoglycemic episodes found that glucagon successfully reversed severe hypoglycemia in 98% of cases, with most patients regaining consciousness within 15 minutes.

Glucagon Formulations

Modern glucagon comes in several formulations, each designed for different use cases:

Injectable Glucagon: The traditional emergency kit. Users or caregivers reconstitute freeze-dried glucagon powder with a pre-filled syringe of diluent and inject intramuscularly or subcutaneously. Fast-acting and reliable, though requires training and a few minutes to prepare.

Nasal Spray Glucagon: Approved by the FDA in 2019, this formulation delivers glucagon powder into the nasal cavity. It's needle-free, requires no reconstitution, and works within 12–15 minutes—almost as fast as injection but dramatically easier for untrained bystanders (including children) to administer. Clinical trials showed nasal glucagon achieved plasma glucose recovery comparable to intramuscular injection, with 92% of patients responding within 30 minutes.

Auto-Injector Glucagon: Pre-filled, auto-injector devices (similar to EpiPens) eliminate reconstitution steps entirely. These are becoming standard in emergency kits because they dramatically reduce preparation time and user error.

Regulatory Status & Approvals

Glucagon has been approved by regulatory authorities globally for decades:

FDA (US): Multiple formulations approved, including Glucagon (Eli Lilly), GlucaGon (Novo Nordisk), and Baqsimi (nasal spray). The FDA's approval documentation is available on their CDER database.
EMA (European Union): GlucaGon and other glucagon products are authorized for use across EU member states under centralized procedure.
Health Canada: Glucagon formulations are approved under the Therapeutic Products Directorate (TPD).

With over 1,000 registered clinical trials worldwide, glucagon is among the most rigorously studied peptide therapeutics. These trials span emergency hypoglycemia treatment, dosing optimization, formulation comparison, and combination therapies.

Clinical Evidence & Efficacy

A meta-analysis of glucagon efficacy across multiple clinical trials found a 97–98% success rate in reversing severe hypoglycemia, with median time to glucose recovery of 10–15 minutes. Success is defined as the patient regaining consciousness and achieving a blood glucose above 70 mg/dL without requiring additional interventions.

Comparative data show that nasal glucagon performs similarly to injectable forms in real-world settings, with the advantage of ease of use. A randomized controlled trial comparing nasal glucagon to intramuscular injection found no significant difference in glucose recovery time or final blood glucose levels.

One important limitation: glucagon works only if the liver has stored glycogen. In cases of prolonged starvation, alcohol-induced hypoglycemia, or certain genetic metabolic disorders, glucagon may be less effective and intravenous glucose (dextrose) remains the gold standard.

Safety Profile

Glucagon has an excellent safety record. Adverse events are rare and typically mild, with nausea and vomiting occurring in fewer than 2% of cases. Serious adverse events are extremely uncommon. The most notable concern is allergic reaction in patients with a history of hypersensitivity to glucagon or any component of the formulation—but this is rare.

Post-treatment hyperglycemia (high blood sugar) is common but expected and generally managed by resuming normal diabetes medications or dietary carbohydrates. There are no known drug-drug interactions of clinical significance, and glucagon can be safely combined with all insulin and oral diabetes medications.

How Glucagon Differs from Related Compounds

While glucagon is the natural hormone, synthetic analogs and glucagon-like peptide-1 (GLP-1) receptor agonists represent related but distinct therapeutic classes. AOD-9604, for example, is a research-stage compound derived from human growth hormone, whereas compounds like Alexamorelin are growth hormone secretagogues targeting different metabolic pathways. Similarly, Amycretin modulates glucose metabolism through different mechanisms entirely. Glucagon remains the gold standard for emergency hypoglycemia reversal because its mechanism—direct liver and muscle glucose mobilization—is unmatched in speed and efficacy.

Patient Considerations

People with diabetes should consider having glucagon readily available if they take insulin or medications that can cause hypoglycemia. Caregivers (family, coworkers, school staff) should be trained in glucagon administration. Many diabetes educators now recommend keeping both an injectable kit and a nasal spray on hand, as nasal spray's ease of use can be life-saving in public settings where an untrained bystander might be the first responder.

Fresh glucagon is essential: kits expire and should be replaced annually. Storage instructions vary slightly by formulation, but most injectable kits should be kept at room temperature away from direct sunlight.

The Future of Glucagon Therapeutics

Research continues on next-generation glucagon formulations and combination therapies. Researchers are exploring oral glucagon, longer-acting formulations, and dual-hormone (insulin + glucagon) artificial pancreas systems. These innovations aim to further reduce the burden of hypoglycemia management and improve outcomes for people with diabetes.

Conclusion

Glucagon is a well-established, FDA- and EMA-approved peptide hormone with unmatched efficacy in treating severe hypoglycemia. With over 1,000 clinical trials documenting its safety and effectiveness, modern formulations (particularly nasal spray) have made emergency hypoglycemia management accessible and intuitive. For anyone taking diabetes medications, understanding glucagon and having it available represents one of the most important safety measures possible.

Glucagon: The Peptide Hormone That Raises Blood Sugar